Brokerages Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $49.18

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $49.6364.

Several research analysts recently issued reports on the company. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Citizens Jmp decreased their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Finally, Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company.

Insider Buying and Selling

In other news, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Viviane Monges sold 9,667 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the sale, the director owned 5,500 shares of the company’s stock, valued at approximately $166,595. This represents a 63.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 215,209 shares of company stock worth $6,431,945 over the last 90 days. 11.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP bought a new position in Pharvaris in the 3rd quarter valued at about $43,282,000. Paradigm Biocapital Advisors LP lifted its position in shares of Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after buying an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Pharvaris during the 3rd quarter worth approximately $15,613,000. Commodore Capital LP lifted its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. lifted its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares in the last quarter.

Pharvaris Stock Up 0.0%

Shares of NASDAQ:PHVS opened at $33.30 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of -10.47 and a beta of -2.35. Pharvaris has a 12-month low of $16.72 and a 12-month high of $35.33. The business has a fifty day simple moving average of $30.47 and a 200 day simple moving average of $27.93.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts expect that Pharvaris will post -3.22 EPS for the current year.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.